SanBio Inc announces it has received Australian Patent 2013263417, covering its proprietary modified stem cells, SB623, for the treatment of traumatic brain injury (TBI). It also recently presented results from a study using SB623 with stroke patients.

The company notes in a media release that Australia was the first country to grant the patent, adding that it will continue to seek patent coverage for this treatment in other regions.

In seeking the patent, the company suggests that SB623 stem cells demonstrate the ability to promote, among other things, regenerative processes in the central nervous system and to provide therapeutic options for debilitating neurological disorders, including traumatic brain injury.

“There are 5.3 million people living with chronic disabilities from traumatic brain injury in the United States and more than 700,000 in Australia. We hope that SanBio’s regenerative medicine, SB623, will be able to serve as a treatment option for these patients,” says Dr Damien Bates, chief medical officer and head of research at SanBio, in the release.

In a separate release, SanBio recently presented 1-year interim results from a Phase 1/2a intracerebral stem cell implant study during the American Congress of Rehabilitation Medicine Conference.

The open-label, single-arm dose escalation study was performed on 18 patients with chronic motor deficits persisting 6 months to 5 years following an ischemic stroke.

Study results suggest that the SB623 stem cell treatment was generally safe, well tolerated, and associated with greater motor function among the patients.

SanBio, based in Tokyo and Mountain View, Calif, has previously received patents regarding methods to treat stroke and retinal degeneration using SB623 stem cells.

[Source(s): SanBio Inc, Business Wire]